中國醫藥(600056.SH):西咪替丁片通過仿製藥一致性評價
格隆匯5月10日丨中國醫藥(600056.SH)公佈,近日,公司下屬全資子公司天方藥業有限公司(以下簡稱“天方有限”)獲得國家藥監局核准簽發的西咪替丁片《藥品補充申請批准通知書》,該藥品通過仿製藥質量和療效一致性評價。
西咪替丁是一種H2受體拮抗劑,有顯著抑制胃酸分泌的作用,能明顯抑制晝夜基礎胃酸分泌,也能抑制由食物、組胺、五肽胃泌素、咖啡因與胰島素等所誘發的胃酸分泌。截至本公吿披露日,該藥品研發費用投入約804.5萬元人民幣(未經審計)。截至本公吿披露日,公司為國內首家通過西咪替丁片一致性評價的企
業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.